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Introduction. Cervical cancer (CC) brachytherapy is performed under patient sedation, general or spinal anesthesia depending on
centers tradition. No data have been reported demonstrating superiority of one the three approaches. Present work analyzes
dosimetric results of application performed under spinal anesthesia or sedation.
Material and methods. 26 consecutive patients with histologically proven CC (FIGO IB to IIIB) underwent radio-chemotherapy
and 3D MR/CT-based IGABT with Fletcher or Utrecht type applicators (Nucletron). 15 patients (group A) received overall 62 BT
application under spinal anesthesia, remaining 11 patients (group B) received overall 47 application under sedation. Rectum,
Bladder and Sigmoid were drawn on CT (all by MF) according GEC-ESTRO guidelines. Vaginal packaging (VP) was contoured on
CT images from lower pelvic bone margin up to the cervix (including applicator). For the present study standard point A plan of
7Gy was applied to all cases and different OARs DVH parameters analyzed.
Results. Median age was 51 (44 in group A and 56 in group B). Median VP volume was signiﬁcantly different between group A or
B (116 cm3 vs. 54). Overall VP volume was strongly correlated 0.0001). Rectum D2cc was 4Gy (group A) and 5.3Gy≤ to Rectum
and Bladder D2cc (p, group B). Bladder D2cc was 5.6Gy and 6.6Gy respectively. The VP volume showed a trend to decrease with
patients’ age. Also analyzing results by age cohort, spinal anesthesia was superior to sedation: Group A>50 years: VP=76.54 cm3;
Rectum D2cc 4.83Gy; Bladder D2cc 6.12. Group A<50 years: VP=129.7 cm3; Rectum D2cc 2.62Gy; Bladder D2cc 5.38. Group B>50
years: VP=47 cm3; Rectum D2cc 5.92Gy; Bladder D2cc 6.72. Group B<50 years: VP=76 cm3; Rectum D2cc 3.53Gy; Bladder D2cc
5.3.
Conclusion. BT insertion under spinal anesthesia allows optimal vaginal packaging thus reducing dose to OARs.
http://dx.doi.org/10.1016/j.rpor.2013.03.059
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After breast-conserving surgery, 90% of local recurrences occur within the index quadrant despite the presence of multicentric
cancers elsewhere in the breast. Thus, restriction of radiation therapy to the tumour bed during surgery might be adequate for
selected patients The Intrabeam (Carl Zeiss) (IB) is an electronic brachytherapy device that can beused to deliver lowenergyX-rays
(50kV) to a lumpectomy cavity at the time of lumpectomy for breast cancer. The randomized phase III TARGiT trial demonstrated
similar recurrence rates to whole breast irradiation (WBI) and a lower overall toxicity proﬁle on short-term follow-up.
Aim. There is not reported experience with IB for breast cancer in Spain. We present the ﬁrst and limited experience in this
setting evaluating prospects of use of IB in Spain: (1) has been described an increased clinically relevant RBE (mean RBE values
of 50-kV X-rays from Intrabeam were 1.26–1.42). Total dose given 20Gy at surface applicator. (2) For selected patients, a single
dose of radiotherapy delivered at the time of surgery by use of targeted intraoperative radiotherapy should be considered as an
alternative to external beam radiotherapy delivered over several weeks. (3) Lumpectomy and Targit boost combined with external
beam radiotherapy results in very low local recurrence rate due to accurate localization and the immediacy of the treatment.
Targit boost might be superior to an external beam boost in its efﬁcacy. (4) Cost reduction both in economical, personal and
quality of life compared with WBI. (5) Other tumour locations are also suitable for this treatment.
Conclusion.While a variety ofAPBI techniques are currently available for clinical use, our early experiencewith IORTshows it iswell
tolerated with low morbidity. Delivery of IORT adds moderate operative time (mean 30min) and require creating subcutaneous
tissue ﬂaps.
http://dx.doi.org/10.1016/j.rpor.2013.03.060
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Introduction. Castilla y León is the largest Spanish region and has a low population density, which does not allow the creation of
highly specialized equipment throughout its territory, so many such services are centralized in a regional referral center. This
means that, to attend these services, patients have to travel considerable distances, with the cost and inconvenience that entails,
both for the patient and for the administration and society in general.
